Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $1,064.00 and $680.00 calculating the mean target price we have $912.52. Given that the stocks previous close was at $779.89 this would indicate that there is a potential upside of 17.0%. The day 50 moving average is $823.52 and the 200 moving average now moves to $777.89. The company has a market cap of 85.13B. The stock price is currently at: $784.22 USD
The potential market cap would be $99,612,642,671 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 20.74, revenue per share of $118.47 and a 9.55% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
